Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 10/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368810 | 0.93 | PPARD (0.44) | MAPTKDM4EPPARDPPARGPPARA | |
| SCHEMBL3375724 | 0.91 | FFAR2 (0.51) | PPARDPPARGPPARAFFAR2FFAR1 | |
| SCHEMBL3368900 | 0.89 | PPARD (0.52) | MAPTPPARDPPARGPPARAFFAR1 | |
| SCHEMBL3369392 | 0.85 | PPARD (0.49) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL3369128 | 0.84 | FFAR2 (0.53) | PPARDPPARGPPARAFFAR2FFAR1 | |
| SCHEMBL3371598 | 0.84 | PPARD (0.59) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL3371978 | 0.83 | FFAR2 (0.43) | MAPTKDM4EPPARDPPARGPPARA | |
| SCHEMBL3371369 | 0.82 | PPARD (0.54) | PPARDPPARGPPARAFFAR1CYP2C9 | |
| SCHEMBL3370886 | 0.81 | PTPN1 (0.51) | MAPTPPARDPPARGPPARAFFAR1 | |
| SCHEMBL3372506 | 0.80 | PPARD (0.49) | MAPTKDM4EPPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537091-B1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | MAPT 4327/4885KDM4E 3260/4885PPARD 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.